Global Acute Coronary Syndrome Market to Reach USD 12.81 Billion by 2031 | CAGR of 5.4%
Category : Healthcare | Published Date : Nov 2024 | Type : Press Release
Acute Coronary Syndrome Market Scope & Overview:
In the newly published report, Consegic Business Intelligence states that the Global Acute Coronary Syndrome Market size was valued at USD 8.38 billion in 2023 and is projected to register a CAGR of 5.4%, reaching USD 12.81 billion by 2031. Acute coronary syndrome (ACS) encompasses conditions like heart attacks and unstable angina caused by reduced blood flow to the heart, necessitating prompt diagnosis and treatment. Key treatments include antiplatelet drugs, thrombolytics, and surgical interventions, with hospitals and specialized cardiac centers being primary care providers for ACS patients.
The report comprises the Acute Coronary Syndrome Market Share, Size & Industry Analysis, By Drug Class (Antiplatelet Drugs, Beta-Blockers, Statins, ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Antithrombotic Agents, Others), By Type (Unstable Angina, Non-ST-Elevation Myocardial Infarction (NSTEMI), ST-Elevation Myocardial Infarction (STEMI)), By Route of Administration (Oral, Injectable), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2024-2031.
The report contains detailed information on Acute Coronary Syndrome Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profile, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
Advancements in diagnostic technologies and the shift toward personalized therapeutics drive market growth, while high treatment costs in low-income regions limit accessibility, presenting opportunities for cost-effective solutions.
Segmental Analysis :
By Drug Class:
- Antiplatelet drugs held the largest share in 2023, essential for preventing blood clots in ACS patients, particularly in high-risk cases requiring dual therapy.
- Statins are anticipated to grow at the fastest rate, driven by their preventive role in reducing recurrent cardiac events through cholesterol management.
By Type:
- ST-elevation myocardial infarction (STEMI) led the market in 2023 due to its severity, often requiring immediate and intensive interventions like percutaneous coronary intervention (PCI).
- Unstable angina is expected to grow fastest, as early detection and targeted therapies become more common to prevent progression to more severe ACS events.
By Route of Administration:
- Oral medications dominated in 2023, preferred for long-term management, including antiplatelets and statins for secondary prevention.
- Injectables are projected to grow rapidly due to their use in acute, emergency settings where fast-acting interventions are necessary.
Based on regions, the global market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.
- North America led the market in 2023, driven by advanced healthcare facilities and early intervention strategies for cardiovascular care.
- Asia-Pacific is projected to grow at the highest rate, fueled by rising cardiovascular cases and improved healthcare access in countries like China and India.
| Report Attributes | Report Details |
| Study Timeline | 2018-2031 |
| Market Size in 2031 | USD 12.81 Billion |
| CAGR (2024-2031) | 5.4% |
| By Drug Class | Antiplatelet Drugs, Beta-Blockers, Statins, ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Antithrombotic Agents, Others |
| By Type | Unstable Angina, Non-ST-Elevation Myocardial Infarction (NSTEMI), ST-Elevation Myocardial Infarction (STEMI) |
| By Route of Administration | Oral, Injectable |
| By End-User | Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Others |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major pharmaceutical companies and healthcare innovators, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Acute Coronary Syndrome Industry:
- Johnson & Johnson Services, Inc. (USA)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Portola Pharmaceuticals, Inc. (USA)
- AbbVie Inc. (USA)
- AstraZeneca (UK)
- Amgen Inc. (USA)
- Bayer AG (Germany)
- Eli Lilly and Company (USA)
- Daiichi Sankyo Company, Limited (Japan)
- GlaxoSmithKline plc (UK)
